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GLUCOCORTICOIDS are potent inhibitors of inflammatory
processes  and  are  widely  used  in  the  treatment  of
asthma. The anti-inflammatory effects are mediated
either by direct binding of the glucocorticoid/gluco-
corticoid receptor complex to glucocorticoid respon-
sive elements in the promoter region of genes, or by
an interaction of this complex with other transcrip-
tion  factors,  in  particular  activating  protein-1  or
nuclear  factor-k B.  Glucocorticoids  inhibit  many
inflammation-associated  molecules  such  as  cyto-
kines, chemokines, arachidonic acid metabolites, and
adhesion  molecules.  In  contrast,  anti-inflammatory
mediators often are up-regulated by glucocorticoids.
In  vivo studies  have  shown  that  treatment  of  asth-
matic patients with inhaled  glucocorticoids inhibits
the  bronchial  inflammation  and  simultaneously
improves  their  lung  function.  In  this  review,  our
current  knowledge  of  the  mechanism  of  action  of
glucocorticoids and their anti-inflammatory potential
in  asthma  is  described.  Since  bronchial  epithelial
cells  may  be  important  targets  for  glucocorticoid
therapy in asthma, the effects of glucocorticoids on
epithelial  expressed  inflammatory  genes  will  be
emphasized.
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Introduction
Glucocorticoids  are  hormones  synthesized  in  the
adrenal cortex and secreted into the blood, where the
levels  of  glucocorticoids  fluctuate  in  a  circadian
mode.  In  humans,  the  naturally  occurring  gluco-
corticoid  is  hydrocortisone (cortisol), which is syn-
thesized from its precursor cortisone.
The  beneficial  effects  of  glucocorticoids  in  asth-
matic  patients  were  first  described  in  1950.
1 Since
then  on,  many  studies  have  focused  on  the  ther-
apeutic potential of glucocorticoids. Several synthetic
glucocorticoids, much more potent than cortisol and
without the unwanted mineralocorticoid side effects,
have been developed. Nowadays, glucocorticoids are
powerful  agents  in  the  treatment  of  inflammatory
diseases  and  are  by  far  the  most  effective  anti-
inflammatory  drugs  used  in  the  treatment  of
asthma.
Mechanism of Action
Although glucocorticoids have been known for a long
period of time, their precise mechanism of action is
still  not  completely  understood.  However,  recent
studies  have  increased  our  understanding  of  their
complex mechanisms of action.
Glucocorticoid receptor
To exert their effects, glucocorticoids need to bind to
a specific cytoplasmic glucocorticoid receptor (GR).
Almost all cells of the body express the GR, but the
number of receptors may vary between different cell
types.
2 Cloning of the GR has revealed that the GR
consists  of  approximately  800  amino  acid  residues,
and that certain areas of the molecule show homol-
ogy  with  other  steroid  receptors,  receptors  for
thyroid hormones, and receptors for retinoic acid.
3–7
All members of the nuclear hormone receptor family
share  a  characteristic  three-domain  structure,  first
described for the human GR. The C-terminal domain
is equal in size in all nuclear receptors studied (about
250 amino acids) and its main function is to bind the
steroid.
8 It also contains the binding sites for the heat
shock proteins (hsp) 90.
9,10 Removal of the steroid-
binding domain results in a constitutively active GR
molecule,  indicating  that  this  part  of  the  molecule
acts  as  a  repressor  of  the  transcription-activation
function.  The  most  conserved  central  domain  is
involved in direct binding of the receptor to DNA. It
contains two distinct loops of protein, each bound at
their base via four cysteine residues to a single zinc
ion, the so-called zinc fingers.
11 These zinc clusters
are involved in binding of the GR to the major groove
of the DNA double helix and play a role in dimeriza-
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12,13 In addition, the central
DNA-binding  domain  has  a  transcription-activation
function.
4,14 The  steroid-binding  and  DNA-binding
domains  are  separated  by  the ‘hinge-region’,  which
contains  sequences  that  are  important  for  nuclear
translocation  and  dimerization.
9,10 The  N-terminal
domain is extremely variable in size (24–600 amino
acids).  Its  precise  role  is  still  uncertain,  but  it  is
required in transcriptional activation.
15
Two different forms of the human  GR have been
described.
3,16These two highly homologous isoforms,
termed GRa and  GRb ,  are  generated  by  alternative
splicing  of  the  human  GR  pre-mRNA.  The  GRb
isoform  differs  from  the  GRa isoform  only  in  its
C-terminal domain, in which the last 50 amino acids
of the latter are replaced by a unique 15 amino acid
sequence.  However,  this  replacement  has  dramatic
functional  consequences,  since  the  GRb isoform  is
unable  to  bind  glucocorticoids  and  to  transduce
ligand-dependent transactivation. However, the phys-
iological  significance  of  the  GRb isoform  remains
questionable, since some recent studies indicate that
this  form  is  not  conserved  among  species  and  no
dominant negative inhibition of GRa activity could be
found.
17,18 Nevertheless, abundant expression of GRb
protein can be found in the epithelial cells lining the
terminal bronchioli of the lung.
19
The  expression  of  the  GR  may  be  regulated  by
numerous factors either at the transcriptional, transla-
tional or post-translational level.
20,21 Glucocorticoids
have been shown to down-regulate the expression of
the GR, both in vitro and  in vivo.
22,23 In  contrast,
inflammatory mediators like interleukin (IL)-1b , IL-4,
tumour  necrosis  factor  (TNF)-a ,  lipopolysaccharide
(LPS)  and  interferon  (IFN)-g have  been  shown  to
increase  glucocorticoid  binding  in  vitro.
24–28 How-
ever,  the  increase  in  GR  numbers  may  be  accom-
panied by a reduced affinity for glucocorticoids.
24,28
Analysis of GR localization  in normal  and asthmatic
lung has not revealed differences in the level or sites
of GR expression.
29
Regulation of gene transcription
In the absence of glucocorticoids, the GR is present
in  the  cytoplasm  of  the  cell  as  a  hetero-oligomer
consisting  of  the  GR  itself,  two  molecules  of  hsp
90, one molecule hsp 70, and one molecule of hsp
56  (which probably  does  not  interact  with  the  GR
itself,  but  interacts  with  hsp  90).
30 –34 Glucocor-
ticoids  enter  the  cytoplasm  of  the  cell  by  passive
diffusion  through  the  cell  membrane.  In  the  cyto-
plasm  they  bind  to  the  GR  complex,  which  subse-
quently  undergoes  conformational  changes,  result-
ing  in  the  dissociation  of  the  hsp  90  and  hsp  56
molecules. Upon  this activation, the glucocorticoid-
GR  complex  passes  the  nuclear  membrane,  enters
the nucleus, and the hsp 70 molecule is dissociated.
Furthermore, in the nucleus liganded GR form hom-
odimers (Fig.  1).
Within  the  nucleus,  the  GR  homodimers  may
regulate  gene  transcription  in  several  ways:  (1)  via
binding of the glucocorticoid-GR complex to specific
DNA sequences, thereby directly activating or repres-
sing genes; (2) via interaction with other transcription
factors; and (3) via modulating the stability of specific
mRNA molecules.
35–39
Binding to DNA sequences
Several  steroid-responsive  genes  contain  glucocor-
ticoid  responsive elements (GRE) in  their  promoter
region.
35,40 Binding of GR homodimers to GRE may
either result in transcriptional activation of the gene
(via a positive GRE) or repression of the gene (via a
negative GRE) (Fig. 1). The consensus sequence for
(positive)  GRE  is  the  palindromic  15-base-pair
sequence GGTACAnnnTGTTCT, whereas the negative
GRE  has  a  more  variable  sequence.
36 The  rate  of
transcriptional regulation of steroid-responsive genes
is dependent on both the numbers of GRE, the affinity
of the glucocorticoid-GR complex to the GRE, and the
position of the GRE relative to the transcriptional start
site.  Binding  of  the  complex  to  GRE  may  result  in
conformational changes in the DNA and exposure of
previously masked areas, resulting in increased bind-
ing of other transcription factors.
41–44
Interaction with other transcription factors
Many  steroid-responsive  genes  do  not  have  GRE  in
their  promoter  region.  However,  binding  sites  for
other  transcription  factors,  including nuclear  factor
(NF)-k B, activating protein (AP)-1, and cAMP-respon-
sive  element  binding  protein  (CREB),  often  can  be
found.
45
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FIG. 1. Schematic representation of the cellular events after
administration of glucocorticoids (adapted from Ref. 39).AP-1,  which  is  a  dimer  of  two  proto-oncogenes
(members  of  the  c-jun  and  c-fos  family),
46,47 is
involved in the regulation of several genes, including
adhesion molecules and cytokines (reviewed in Ref.
47). Direct protein–protein interaction between AP-1
and the glucocorticoid-GR complex results in recipro-
cal repression of one another’s transcriptional activa-
tion  by  preventing  binding  of  the AP-1  and  gluco-
corticoid-GR  complex  to  AP-1  sites  and  GRE,
respectively (Fig. 1).
37,48,49
Comparable to AP-1, NF-k B (a heterodimer of p50
and p65 subunits
50,51) regulates the transcription of
several  genes  involved  in  inflammatory  reac-
tions.
50,52,53 In unstimulated cells, NF-k B is retained in
the cytoplasm of the cells through the interaction with
the inhibitors Ik Ba and Ik Bb .
54–56 Upon cell stimula-
tion, for example by IL-1b or TNF-a , Ik B are rapidly
phosphorylated, ubiquitinated, and consequently pro-
teolysed.
53,57 The liberated NF-k B dimers translocate
to the nucleus where they can activate target genes.
Glucocorticoids  may  inhibit  NF-k B-stimulated  genes
by a direct interaction between the glucocorticoid-GR
complex and the p65 subunit of NF-k B, resulting in
transrepression (Fig. 1).
51,55,58,59 Furthermore, gluco-
corticoids may indirectly antagonize NF-k B mediated
transcription  by  up-regulating  the  synthesis  of  the
inhibitory protein Ik Ba , which traps NF-k B in inactive
cytoplasmic  complexes.
39,54,55 A  large  number  of
immunoregulatory  genes,  whose  expression  is
induced by a variety of pro-inflammatory mediators,
contain  NF-k B  sites  in  their  promoters/regulatory
regions. Therefore, it is no wonder that glucocorticoids
have been found to prevent the expression of these
genes, including those coding for IL-1b , IL-2, IL-6, IL-8,
monocyte chemoattractant protein (MCP)-1, RANTES
(Regulated upon Activation, Normal T cell Expressed,
and  presumably  Secreted),  granulocyte  macrophage
colony-stimulating factor (GM-CSF), the IL-2 receptor,
intercellular  adhesion  molecule  (ICAM)-1,  and
E-selectin (reviewed in Ref. 45). Probably, interactions
between  glucocorticoids  and  NF-k B  or  AP-1  will
explain most of the anti-inflammatory and  immuno-
suppressive activities of glucocorticoids.
An  interaction  between  CREB  and  the  gluco-
corticoid-GR  complex  has  also  been  suggested.
60,61
b -agonists, which are used as bronchodilators in the
treatment  of  asthma,  increase  cAMP  formation  and
subsequently activate CREB. Therefore, simultaneous
treatment of asthmatic patients with glucocorticoids
and b -agonists may result in reduced responsiveness
of the airways for steroids.
61–63
Modulation of mRNA stability.
A  third  mechanism  by  which  glucocorticoids  may
regulate  the  synthesis  of  proteins  is  via  enhanced
transcription of specific ribonucleases which are able
to  degrade  mRNA  containing  constitutive  AU-rich
sequences in the untranslated 39 -region.
64 Such gluco-
corticoid-mediated  modulation  of  post-translational
events  (resulting  in  decreased  mRNA  stability  and
reduced half-life time) has been observed for IL-1b , IL-
6 and GM-CSF .
65,66
Glucocorticoid Regulated Genes
Glucocorticoids  are  able to  modulate  the  transcrip-
tion  of  a  variety  of  genes,  including  cytokines  and
chemokines,  receptors,  enzymes,  adhesion  mole-
cules, and inhibitory proteins (Table 1). Since epithe-
lial cells may be one of the most important targets for
glucocorticoid  therapy  in  asthma,  the  effects  of
glucocorticoids on epithelial expressed inflammatory
genes will be emphasized in this review.
Cytokines and chemokines
Glucocorticoids  inhibit  the  transcription  of  most
cytokines and chemokines that are relevant in asthma,
including IL-1b , TNF-a , GM-CSF, IL-3, IL-4, IL-5, IL-6, IL-
8,  IL-11,  IL-12,  IL-13,  RANTES,  eotaxin,  and  macro-
phage  inhibitory  protein  (MIP)-1a .
45,66 In  general,
reduced synthesis of these mediators may result in a
decreased recruitment  and  activation  of leukocytes,
also indirectly due to effects on adhesion molecules
and  cell  survival.  Since  many  cytokine  gene  pro-
moters do not contain a negative GRE, the effects of
glucocorticoids on cytokine and chemokine produc-
tion are probably mediated via an effect on a critical
transcription  factor  (especially  NF-k B  and  AP-1).
67
Cross-signalling between NF-k B and AP-1 with gluco-
corticoid/GR  complex  have  indeed  been  demon-
strated in bronchial epithelial cells.
67
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Table  1.  Influence  of  glucocorticoids  on  the  synthesis  of
proteins  with inflammatory  effects by  bronchial  epithelial
cells
Protein Glucocorticoid
effect
Cytokines
IL-1b , IL-6, IL-11, TNF-a , GM-CSF ¯
IL-10, LIF ?
G-CSF =
Chemokines
MCP-1, eotaxin, IL-8, RANTES, MIP-1a ¯
Receptors
NK, GR ¯
IL-1R II, IL-6R, b 2-adrenergic receptor ›
Enzymes
iNOS, COX-2, cPLA2 ¯
NEP ›
Adhesion molecules
ICAM-1 ¯
Inhibitory proteins
Lc-1 =/›
IL-1RA type I, SPLI ›Bronchial epithelial cells are capable of producing a
variety of cytokines and chemokines that may contrib-
ute  to  the  initiation  and  perpetuation  of  airway
inflammation.  Several studies have shown that cyto-
kine-induced  expression  of  eotaxin,  IL-6,  IL-8,  GM-
CSF ,  and  RANTES  can  be  diminished  by  gluco-
corticoids in vitro.
68–76 In  contrast, glucocorticoids
did  not modulate the secretion of G-CSF by human
bronchial  epithelial  cells.
76 In  vivo studies  have
shown that treatment with inhaled steroids decreases
both the expression of GM-CSF,
77 IL-1b ,
78 IL-8,
79 and
RANTES
80 by the bronchial epithelium, together with
the  number  of  activated  eosinophils  in  the
epithelium.
Receptors
Glucocorticoids  may  modulate  the  expression  of
several  receptors. The expression of the neurokinin
(NK)1 receptor,  which  mediates  many  effects  of
substance P (SP) in the airways and is believed to be
up-regulated in asthma,
81 is down-regulated by gluco-
corticoids.
82 Since the NK1 receptor gene promoter
region has no GRE but has an AP-1 response element,
this  effect  probably  will  be  mediated  via  an  inter-
action of the glucocorticoid-GR complex with AP-1.
In  contrast  to  NK1 receptors,  expression  of  the
b 2-adrenergic  receptor  is  increased  by  glucocor-
ticoids.
83 Since  the  human  b 2-adrenergic  receptor
gene  contains  three  potential  GRE,  this  effect  of
glucocorticoids probably is a direct one.
83 Up-regula-
tion  of  b 2-adrenergic  receptors  by  glucocorticoids
may be relevant  in asthma as it may prevent down-
regulation  in response to prolonged treatment with
b 2-agonists.
84
The  IL-1  receptor  type  II,  which  functions  as  a
decoy receptor,
85 may also be up-regulated by gluco-
corticoids, thereby reducing the functional activity of
IL-1 agonists.
86,87 Soluble TNF-receptor type I (p55)
release  by  human  bronchial  epithelial  cells,  both
constitutive as well as IL-1b -induced, has been shown
to  be  reduced  by  glucocorticoids.
88 In  contrast,
glucocorticoids  up-regulate  the  expression  of  IL-6
receptors  in  rat  hepatoma  and  human  epithelial
cells.
89,90 Thus far little is known about this process in
human bronchial epithelial cells, which constitutively
express these receptors.
91
Glucocorticoids  also  modulate  the  expression  of
their own receptor. In a recent study it was shown
that expression of the a -form (but not the b -form) of
the GR in human bronchial epithelial cells was down-
regulated in healthy subjects after 4 weeks of budeso-
nide inhalation.
23
Enzymes
Glucocorticoids  inhibit  the  synthesis  of  several
inflammatory mediators implicated in the pathogene-
sis of asthma through an inhibitory effect on enzyme
induction.  The  synthesis  of  inducible  nitric  oxide
synthase (iNOS) by  human  airway epithelial  cells is
inhibited  by  glucocorticoids,  both  in  vitro and  in
vivo.
92 –94 This  effect  seems  to  be  mediated  via
inactivation  of  NF-k B.
95,96 Since  nitric  oxide  (NO)
may  contribute  to  skewing  of  Th  lymphocytes
towards  a  Th2  phenotype,  thereby  promoting  IgE
production and eosinophil recruitment, inhibition of
iNOS  may  be  of  importance  in  anti-inflammatory
therapy in asthma.
97
Glucocorticoids also inhibit the gene transcription
of a cytosolic form of phospholipase A2 induced by
cytokines
98 and  inhibit  the  gene  expression  of
cyclooxygenase-2, resulting in reduced formation of
prostaglandins and thromboxanes.
99
In  contrast  to  the  enzymes  mentioned  above,
glucocorticoids  have  been  shown  to  increase  the
expression  of  neutral  endopeptidase  (NEP),
100–102
thereby potentially limiting neurogenic inflammatory
responses.
103 In accordance with these results, it was
found  that  the  expression  of  NEP  on  bronchial
epithelial  cells  was  higher  in  asthmatics  treated
with  steroids  compared  with  nonsteroid-treated
asthmatics.
104
Endothelins
Endothelins  are  a  family  of  highly  homologous
21-amino  acid  peptides, characterized by  two intra-
chain disulphide chains, a hairpin loop consisting of
polar  amino  acids,  and  a  hydrophobic  C-terminal
chain.
105 Human bronchial epithelial cells have been
shown to  produce ET-1,
106 –108 which promotes the
proliferation  of  smooth  muscle  cells,  is  a  potent
constrictor of both vascular and non-vascular smooth
muscle cells, increases the secretion  of mucus, and
may  activate  inflammatory  cells.
105,107,109 ET-1  also
stimulates collagen gene expression and through its
inhibitory actions on collagenase will promote airway
wall  collagen  deposition,  thereby  contributing  to
airway  wall  thickening  which  underlies  bronchial
hyperresponsiveness.
110–112 Increased  levels  of  ET-
1-immunoreactivity  were detected in  airway  epithe-
lium  and  vascular  endothelium  of  bronchial  biopsy
specimens  from  nonsteroid-treated  asthmatics  com-
pared with healthy subjects.
106,113,114 In contrast, no
increased ET-1 expression was found in the bronchial
epithelium  of  asthmatic  patients  treated  with
glucocorticoids.
115
Adhesion molecules
Adhesion  molecules  play  an  important  role  in  the
recruitment  of  inflammatory  cells  to  the  inflamma-
tory  locus.  Expression  of  adhesion  molecules  on
endothelial, epithelial or inflammatory cells is often
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reduce  surface  expression  of  adhesion  molecules.
This effect may be due either to inhibition of cytokine
synthesis or to a direct effect of glucocorticoids on
adhesion  molecule  gene  transcription.  It  has  been
shown  that  the  expression  of  ICAM-1,  endothelial
leukocyte adhesion molecule (ELAM)-1, and E-selectin
is down-regulated by steroids.
116 Basal and cytokine-
stimulated  ICAM-1  expression  on  human  bronchial
epithelial  cell  lines  is  inhibited  by  glucocor-
ticoids.
117,118 However,  inhaled  glucocorticoids  did
not modulate ICAM-1 expression by bronchial epithe-
lial cells from asthmatics in vivo.
119
Eosinophil  adhesion  to  cytokine-stimulated  bron-
chial epithelial cells was shown to be inhibited by the
synthetic glucocorticoid dexamethasone.
120 Although
cytokine-activated  epithelial  cells  showed  increased
expression of ICAM-1, this molecule did not seem to
be involved in the decreased adhesion of eosinophils
observed in the presence of dexamethasone.
120
Inhibitory proteins
The anti-inflammatory effects of glucocorticoids may
be mediated by increasing the production of inhibi-
tory  proteins,  such  as  lipocortins.  Lipocortins  are
members of a superfamily of proteins characterized
by their ability to bind calcium and anionic phospho-
lipids, now known as the ‘annexins’.
121,122 In several
cell types, but not all, glucocorticoids are inducers of
lipocortins,  which have  an  inhibitory  effect  on  the
activity  of  phospholipase A2.
123,124 As  a  result,  the
synthesis of lipid mediators, including prostaglandins
and eicosanoids, will be reduced. However, in human
bronchial epithelial cells glucocorticoids do not seem
to up-regulate the expression  of lipocortins.
125 Fur-
thermore,  no  significant  difference  was  found
between lipocortin-1 concentration in BAL fluid from
asthmatic  patients  receiving  inhaled  glucocorticoid
therapy  and  those  who  were  not  treated  with
glucocorticoids.
126
Recently, glucocorticoids have also been shown to
increase the expression of intracellular IL-1 receptor
antagonist type I by human bronchial epithelial cells
in  vitro.
127 Increased  production  of  this  mediator
may  inhibit  the  effects  of  IL-1  agonists,  thereby
reducing  inflammation.  However,  glucocorticoid
treatment  of  asthmatic  patients  did  not  affect  the
expression  of IL-1  receptor  antagonist by  the bron-
chial epithelium.
78
To provide protection against potentially injurious
agents,  airway  epithelial  cells  secrete  a  number  of
mediators,  including  antiproteases.  Secretory  leuko-
cyte  protease  inhibitor  (SLPI)  is  the  predominant
antiprotease in the airways. Its expression has been
shown to be increased in airway epithelial cells after
stimulation with glucocorticoids.
128
Cellular and Clinical Effects of
Glucocorticoids in Asthma
Several studies have determined the effects of inhaled
glucocorticoids on bronchial inflammation, either by
measurements in BAL fluid, sputum, or exhaled air, or
by  performing  bronchial  biopsies.  Although  differ-
ences can be observed between different trials, these
studies have confirmed that glucocorticoid treatment
of asthmatic patients reduces the number and activa-
tion  of  inflammatory  cells  in  the  airways,  together
with  an  improvement  of  lung  function.  Nowadays,
the  potent  anti-inflammatory  actions  of  glucocor-
ticoids are thought to underlie the clinical efficacy of
oral glucocorticoids.
129
Effects of glucocorticoids on immunopathology
Inhaled  glucocorticoids  decrease  the  number  and
activation  status  of  most  inflammatory  cells  in  the
bronchus, including mast cells, dendritic cells, eosino-
phils, and T lymphocytes. Changes in cellular infiltra-
tion  are  accompanied  by  modulated  expression  of
several cytokines. Inhaled glucocorticoids have been
shown to decrease mRNA expression of GM-CSF, IL-
13, IL-4, and IL-5, whereas mRNA levels of IL-12 and
IFN-g increased,  suggesting  a  shift  from  a  Th2-
towards a more Th1-like environment.
77,130,131
Glucocorticoid  treatment  is  associated  with  a
reduction  in  mast  cell numbers  in  the  bron-
chus
79,129,132–135 and  with  reduced  mast  cell  asso-
ciated mediators in BAL fluid.
135,136 This may be due
to a reduction in IL-3 and stem cell factor production,
which are necessary for the survival of mast cells in
tissue. The (IgE-dependent) release of mediators from
mast  cells  does  not  seem  to  be  affected  by  gluco-
corticoid treatment.
137,138
Dendritic cells play an important role in presenting
antigens  to  (naive)  T  cells.
139,140 Inhaled  gluco-
corticoids have  been  shown  to reduce the  number
of  dendritic  cells  in  the  human  bronchial
epithelium.
141
Increased numbers of eosinophils are a prominent
feature  of asthmatic  airways.
142–148 In vitro studies
have shown that many eosinophil functions, includ-
ing adherence and chemotaxis, are diminished follow-
ing glucocorticoid treatment.
138 However, most data
suggest that eosinophil responses to steroids are likely
to be indirect, since eosinophil function is markedly
affected by cytokines elaborated from T lymphocytes
(IL-3, IL-4, IL-5, GM-CSF), endothelial cells (GM-CSF)
and  epithelial cells (GM-CSF).
149 –153 In vivo studies
indicate that treatment with inhaled steroids reduces
the  number  of  eosinophils  and  eosinophil-related
mediators  in  BAL  fluid
79,148,154 and  the  number
of  (activated)  eosinophils  in  bronchial  biop-
sies.
79,129,132,133,155 Recently,  induced  sputum  has
been  suggested  as  a  useful  tool  for  evaluating  the
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Mediators of Inflammation · Vol 7 · 1998 233effects of therapy on  airway  mucosal inflammation.
Thus far, most studies have focused on the presence
of  eosinophils  and  eosinophil-related  mediators.  In
accordance  with  the  findings  in  BAL  fluid  and
bronchial  biopsies,  glucocorticoid  treatment  was
associated  with  a  reduction  in  sputum  eosinophil
numbers,  eosinophil  cationic  protein  (ECP),  and
eosinophil peroxidase (EPO).
156
Glucocorticoids  also  reduce  the  number  of  acti-
vated T lymphocytes in  bronchial  biopsies and  BAL
fluid.
129,133,134,155,157 In addition,  inhaled corticoste-
roids reduced the number of cells expressing mRNA
for  IL-4  or  IL-5,  and  increased  the  number  of  cells
expressing mRNA for IFN-g ,
131,132 thereby favouring
the development of Th1 cells.
158
In  addition  to  the  effects  of  glucocorticoids  on
epithelial  cells  described  above,  inhaled  glucocor-
ticoid therapy has been  shown  to reduce the shed-
ding of epithelial cells.
155,159,160 No consistent effect
of corticosteroids on the thickness of the basement
membrane has been observed.
79,160,161
Besides  the  suppressive  effects  on  inflammatory
cells,  inhaled  glucocorticoids  have  also  shown  to
inhibit mucus secretion and microvascular leakage (as
determined  by  the  down-regulation  of  plasma  pro-
teins in BAL fluid).
160,162–166 At present it is not clear
whether  this  is  mediated  via  a  direct  effect  of
glucocorticoids on endothelial or mucous cells, or via
a reduction of inflammatory mediators that increase
mucus secretion and vascular leakage.
Effects of glucocorticoids on lung function
Treatment with glucocorticoids has been consistently
shown not only to reduce the symptoms of asthma,
but also bronchial hyperresponsiveness.
134,167–169 In
contrast to the rapid inhibitory effects of b 2-agonists,
glucocorticoids given in a single dose are not effective
in preventing early allergen-invoked bronchoconstric-
tion,  but  inhibition  of  the  late  response  has  been
clearly demonstrated.
170,171 In contrast, chronic treat-
ment with either oral or inhaled steroids attenuates
even the early bronchoconstriction to allergen,
171–173
an  effect  that  probably  is  mediated  via  the  anti-
inflammatory  actions  of  glucocorticoids  already
described.  Although  inhaled  glucocorticoids  con-
sistently  reduce  airway  hyperreactivity  in  asthmat-
ics,
169 even after several months of treatment respon-
siveness fails to return to the normal range. This may
reflect persistence of structural changes that cannot
be reversed by steroids (such as the thickening of the
basement membrane), despite of suppression of the
inflammatory and immunological processes.
Concluding Remarks
Glucocorticoids are widely used in the treatment of
asthma  and  have  anti-inflammatory  effects.  These
effects are mediated either by direct binding of the
glucocorticoid/GR complex to GRE in the promoter
region of responsive genes, or by an interaction of this
complex with transcription factors such as AP-1 and
NF-k B.  Glucocorticoids  inhibit  the  expression  of  a
large number of inflammation-associated molecules,
including  cytokines,  chemokines,  arachidonic  acid
metabolites,  and  adhesion  molecules. These  effects
predominantly  are mediated via inhibition  of NF-k B
activity.  In  contrast,  anti-inflammatory  mediators,
such as NEP and IL-1 receptor antagonist, often are
up-regulated by glucocorticoids. The beneficial effects
of glucocorticoid therapy in asthma is demonstrated
by  in  vivo studies  showing  that  treatment  of  asth-
matic  patients with  inhaled glucocorticoids inhibits
the inflammation of the airways and simultaneously
improves their  lung  function. These  effects may  be
mediated  in  part  by  modulation  of  epithelial  cell
functions, since many  studies, both in vitro and  in
vivo,  have  shown  that  glucocorticoids  are  able  to
modulate  the  inflammatory  functions  of  bronchial
epithelial cells. Further studies on the mechanism of
action of glucocorticoids will eventually lead to the
development of drugs which specifically inhibit  the
transcription  of inflammatory genes without having
negative side effects, and will contribute to a more
efficient treatment of asthmatic patients.
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